It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Study R-20-0085: COVID-19: Immunogenicity of BNT162b2 in mice
Study R-20-0112: Characterizing the immunophenotype in spleen and lymph node of mice treated with SARS-CoV-2 vaccine candidates
Study R-20-0072: Biodistribution of BNT162b2 using the luciferase protein as a surrogate marker protein after intramuscular injection in mice. Toxicology
The vaccine was tested for its ability to result in S protein expression in a mammalian cell population in vitro, for its immunogenicity in mice in two studies, and in one study in rhesus monkeys, including its capacity to prevent disease after challenge with SARS Cov-2 virus in rhesus monkeys. The vaccine also induced an immune response in rats in the two toxicity studies.
originally posted by: bastion
a reply to: and14263
Malone is wrong, it's best not to quote him if you want a case to be taken seriously as most of his claims are made up.
The animal trials were done on several species of monkeys, mice, rats and syrian hamsters as Phase I. It's all public data and has been since early May 2020 when the trials were done.
originally posted by: and14263
I mentioned earlier that I travel for work but will not be having a 'booster' injection, even if it means I cannot travel and carry out my job properly.
I think I am building a strong enough case to present to management to support my decision.
I need help on one part regarding vaccine trials.
You are all probably familiar with Dr Robert Malone's presentation regarding the shortfalls and problems with the Pfizer vaccine trials. If you are not, here's a link to the PDF: Link to PDF.
In this presentation it states:
Animal testing was skipped.
However, back in June (I think) the UK Government published an assessment of the vaccine trials for the exact same vaccine, this assessment is here: Link to assessment.
In this assessment it states:
Study R-20-0085: COVID-19: Immunogenicity of BNT162b2 in mice
Study R-20-0112: Characterizing the immunophenotype in spleen and lymph node of mice treated with SARS-CoV-2 vaccine candidates
Study R-20-0072: Biodistribution of BNT162b2 using the luciferase protein as a surrogate marker protein after intramuscular injection in mice. Toxicology
The vaccine was tested for its ability to result in S protein expression in a mammalian cell population in vitro, for its immunogenicity in mice in two studies, and in one study in rhesus monkeys, including its capacity to prevent disease after challenge with SARS Cov-2 virus in rhesus monkeys. The vaccine also induced an immune response in rats in the two toxicity studies.
Can anyone explain to me or help me argue in opposition to this? To me, it clearly refutes Dr Malone's statement. I am almost certain Dr Malone and the UK Gov document are discussing the exact same trial because they describe the same number of participants (43,000) and the exact same vaccine (BNT162b2).
How do I counter this objection I have found whilst researching? It's not the be all and end all, I have written a pretty robust case in favour of sensibly not having a booster injection, but if I can explain this anomaly away it would REALLY help my case.
originally posted by: and14263
a reply to: Acknt
Thanks.
Do you have any specific details? Like what the animal trials should have looked like, compared to what these look like?
I will of course take your information and start looking at the specifics of animal trails in vaccines now.
originally posted by: and14263
a reply to: Acknt
Thanks.
Do you have any specific details? Like what the animal trials should have looked like, compared to what these look like?
I will of course take your information and start looking at the specifics of animal trails in vaccines now.
originally posted by: SoundisVibration
a reply to: and14263
If you're looking to help disprove the vaccine, you can see in this article and the links within it,
M oderna and Pfizer botched their long term trial by telling placebo patients they were not immunized
Are animal models predictive for humans? Currently, nine out of ten experimental drugs fail in clinical studies because we cannot accurately predict how they will behave in people based on laboratory and animal studies
originally posted by: and14263
I mentioned earlier that I travel for work but will not be having a 'booster' injection, even if it means I cannot travel and carry out my job properly.
I think I am building a strong enough case to present to management to support my decision.
I need help on one part regarding vaccine trials.
You are all probably familiar with Dr Robert Malone's presentation regarding the shortfalls and problems with the Pfizer vaccine trials. If you are not, here's a link to the PDF: Link to PDF.
In this presentation it states:
Animal testing was skipped.
However, back in June (I think) the UK Government published an assessment of the vaccine trials for the exact same vaccine, this assessment is here: Link to assessment.
In this assessment it states:
Study R-20-0085: COVID-19: Immunogenicity of BNT162b2 in mice
Study R-20-0112: Characterizing the immunophenotype in spleen and lymph node of mice treated with SARS-CoV-2 vaccine candidates
Study R-20-0072: Biodistribution of BNT162b2 using the luciferase protein as a surrogate marker protein after intramuscular injection in mice. Toxicology
The vaccine was tested for its ability to result in S protein expression in a mammalian cell population in vitro, for its immunogenicity in mice in two studies, and in one study in rhesus monkeys, including its capacity to prevent disease after challenge with SARS Cov-2 virus in rhesus monkeys. The vaccine also induced an immune response in rats in the two toxicity studies.
Can anyone explain to me or help me argue in opposition to this? To me, it clearly refutes Dr Malone's statement. I am almost certain Dr Malone and the UK Gov document are discussing the exact same trial because they describe the same number of participants (43,000) and the exact same vaccine (BNT162b2).
How do I counter this objection I have found whilst researching? It's not the be all and end all, I have written a pretty robust case in favour of sensibly not having a booster injection, but if I can explain this anomaly away it would REALLY help my case.